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Abstract
The combined treatment with Cytomix + Guna liver + Interferon gamma was favorized the improvement of clinical symptoms in patients 
with HVBC, HVC and HVBC+HVCC, the decrease and normalization of liver and spleen sizes, moderate decrease of cytolisis indices values 
(ALAT, ASAT), seroconversion in the AgHBs and anti-Hbs system with the formation of anti-HBs (protective antibodies) in 2 patients with 
the diagnosis HVBC and in one patient with the mixed hepatitis HVBC+HVCC.  The improvement of immune status indices, which was more 
marked in patients with HVCC there were not noted clinical, biochemical and immunological improvement in patients of the control group.
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Kомбинированное лечение Цитомиксом, Гуна ливером, Интерфероном гамма больных хроническим вирусным гепатитом 
В и С и микст гепатитом В+С
Комбинированное лечение Цитомиксом, Гуна ливером, Интерфероном гамма привело к исчезновению клинической симптоматики 
у больных хроническим вирусным гепатитом В и С и микст гепатитом В+С, с нормализацией размеров печени и селезенки и умеренным 
снижением активности АЛАТ и АСАТ.  Произошла сероконверсия в системе НBsAg и анти-HBs с образованием анти-HBs у двух больных 
с хроническим вирусным гепатитом В и у одного с микст гепатитом В+С.  Наблюдалось улучшение иммунологического статуса более 
выраженное у больных с хроническим вирусным гепатитом С.  У пациентов контрольной группы клинические, биохимические, и 
иммунологические улучшения не выявлены.
Ключевые слова: гепатит В, хронический, гепатит С, хронический, Цитомикс, Гуна ливер, Интерферон гамма.
Introduction
The viral hepatitis problem remains to be one of worldwide 
significance, their consequences affecting the health of hundreds 
of million of people.  Both viral acute and chronic hepatitis make 
a touchstone.  New therapeutically methods appeared recently in 
medical practice/first of ale antiviral which has counter indica-
tions and side effects.  Only 30–40% of patients usually benefit 
of antiviral treatment, but what about the rest?
The purpose of the study was to determine the efficiency 
of Cytomix therapy + Guna liver + Interferon gamma in viral 
chronic hepatitis B, C and B and C
Material and methods
2 patients groups were been included in the study: - I (first) 
group of patients, who were administered three therapy with 
Cytomix+Interferon gamma+Guna liver – 17 patients;
- II (second) control group – 16 patients.
17 patients have been included in the experimental group, 
who were administered three therapy: 9 men and 8 women 
aged between 18 and 80 years, among them 8 had the diag-
nosis HVBC, the disease stage was between 1 and 13 years. 
7 patients had the diagnosis HVCC, the disease stage was 
between 1 and 9 years and 2 patients with mixed chronic viral 
hepatitis B+C, in one patient the disease stage was equal with 
1 year and in the second HVBC was detected 28 years ago, 
and HVCC was revealed 2 years ago.
There were included 16 patients in the control group: 10 
men and 6 women aged between 27 and 72 years.  Among, 
them 6 patients with the diagnosis of HVBC and 8 patients 
with the diagnosis HVCC, and 2 patients with the mixed 
chronic viral hepatitis B+C.  The disease length was between 
5 to 17 years in patients with HVBC.  The disease length was 
between 1 to 12 years in patients with HVCC.  The disease 
length in patients with mixed chronic viral hepatitis B+C was: 
in one patient both hepatitis forms were traced out 8 years 
before and in the second patient HVCC was diagnosed 12 
years ago, and HVBC – 10 years ago.
The clinical exam
Patients with HVCC, HVBC and mixed HVCC+HVBC 
were clinically examined: anamnesis, liver and spleen palpa-
tion and percussion, chest auscultation and percussion and 
heart auscultation if needed.
The dynamics of paraclinical and clinical investigations
Laboratory exams: serologic investigations: the reveal of 
AgHBe, anti-HBe, anti-HBs, anti-HVC IgM; biochemistry 
investigations: the values determination of ALAT, ASAT, bi-
lirubin, thymol test, prothrombin; clinical exam – hemogram 
and immunological status were made at the start and at the 
end of treatment.
The treatment lasted for 3 months.
The modality of medicines administration in the first 
group was
The first month of treatment:
1.  Interferon gamma – 26 days, 20 drops twice a day sub-
lingual (in the morning and evening) one hour before 
meals or one hour after meals.  On Sundays the medicine 
was not administered.
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2.  Guna Liver – 26 days, 3 granules twice a day sublin-
gual in the morning and evening one hour before the 
meals or one hour after the meals.  The medicine was 
indicated the next 15 minutes after the administration 
of Interferon gamma.
3.  Cytomix 10 granules twice a day sublingual, in the 
morning and evening the first 5 days, the next 21 days 
3 granules twice a day sublingual, in the morning and 
evening 15 minutes after administration of Guna Liver. 
On Sundays the medicine was not administered.
The second and the third month of treatment
1. Cytomix - 26 days 3 granules twice a day sublingual in 
the morning and the evening one hour before the meals 
or one hour after the meals.
2. Guna Liver - 26 days 3 granules twice a day sublingual 
in the morning and evening 15 minutes after Cytomix 
administration.
3. Interferon gamma - 26 days 20 drops twice a day sub-
lingual in the morning and evening 15 minutes after 
Guna Liver administration.
Results and discussion
Tab. 1 demonstrating the symptomatology poverty, but 
more frequent were revealed next symptoms: pains in the 
right hypochondrium, asthenia, hepatomegalia, spleenome-
galy.  The clinical symptomatology was richer at the treatment 
start in patients with HVBC.  They demonstrated one larger 
gamma of symptoms comparatively with patients with HVCC 
and HVBC+HVCC.
The clinical symptomatology had ameliorated after 3 
months of treatment and at the end of it were persisting only 
2 clinical symptoms: asthenia and pains in right the hypo-
chondrium in patients with HVBC.  The liver and spleen 
dimensions had decreased in all three groups with over 50% 
at the treatment’ end comparatively with the liver and spleen 
dimensions at the treatment’s start.
The clinical symptomatology in patients of the control 
group (tab. 2), demonstrating the poverty of clinical manifes-
tations, they being quite the same both in patients with HVBC 
and HVCC.  But the evolution analysis of these symptoms in 
dynamics had revealed its insignificant amelioration.  Hepa-
tomegaly and spleenomegaly were the revealed with the same 
frequency – 83% and 87.5% respectively at the start and the 
end of the study.
The analysis of biochemistry indices in patients of the 
experimental group (tab. 3) conducts us to some conclusions:
ALAT had normalized in a small number of patients - 2 
with HVBC and 4 with HVCC, and the increased ASAT values 
had normalized in 4 patients, and had increased discreetly in 
4 patients with normal values.
Table 1
Clinical symptomatology and its evolution dynamics in patients of the experimental group and of the control group
Symptom
At the treatment’s start At the treatment’s end
HVBC
n = 8
HVCC
n = 7
HVBB+
HVCC
n = 2
HVBC
n = 8
HVCC
n = 7
HVBB+
HVCC
n = 2
Asthenia 3 (37.5%) - 1 1 (12.5%) - -
Pains in the right hypochondrium 5 (62.5%) 2 (28.5%) - 1 (12.5%) - -
Vertigo 2 (25%) - - - - -
Myalgia 1 (12.5%) 2 (28.5%) 1 - - -
Arthralgia 1 (12.5%) 2 (28.5%) - - - -
Nausea 2 (25%) - 1 - - -
General weakness 2 (25%) - - - - -
Pruritus 1 (12.5%) - - - - -
Hepatomegalia 6 (75%) 5 (71.7%) 2 2 (25%) 3 (43%) 1
Spleenomegaly 5 (62.5) 3 (43%) 1 1 (12.5%) 1 (14.3%) 1
Table 2
Clinical symptomatology and its evolution dynamics patients of the control group
Symptoms
At the treatment’s start At the treatment’s end
HVBC
n = 6
HVCC
n = 8
HVBB+
HVCC
n = 2
HVBC
n = 6
HVCC
n = 8
HVBB+
HVCC
n = 2
Asthenia 5 (83%) 2 (25%) - 4 (66.6%) 1 (12.5%) -
Pains in the right hypochondrium 3 (50%) 5 (62%) 1 3 (50%) 2 (25%) -
Vertigo - 1 (12.5%) - - 1 (12.5) -
Myalgia 1 (16.6%) - - - - -
Arthralgia 1 (16.6%) 2 (25%) - - 2 (25%) -
Nousea 1 (16.6%) 1 (12.5%) - 1 (16.6%) 1 (12.5) -
General weakness 3 (50%) 2 (25%) - 3 (50%) 1 (12.5) -
Prurigo - - - - - -
Hepatomegalia 5 (83%) 7 (87.5) 1 5 (83%) 7 (87.5%) 1
Splenomegaly 5 (83%)q 4 (50%) 2 5 (83%) 4 (50%) 2
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Bilirubin increased values had been revealed in patients 
with the Gilbert’s Syndrome - 30 mcmol/l and 24 mcmol/l.
Thymol test values did not modify.
The prothrombin index was normal in the majority of 
patients included in the study and only in one patient with the 
diagnosis HVBC and 2 with HVCC had decreased with 80 – 70%.
The analysis of biochemistry indices in patients of the 
control group (tab. 4) to find one absence of modifications 
in biochemistry indices during three months of observation. 
The increased bilirubin level was revealed in patients with 
Gilbert’s Syndrome.  The prothrombinic index was decrea-
sed - in 2 patients with HVBC, 3 – with HVCC and 2 – with 
HVBC+HVCC, its values being between 80 and 70%.
The tab. 5 shows the AgHBe reveal at the start and the end 
of treatment in the same patients, seroconversion of HBe-anti-
HBe had not happened.
AntiHBs had formed in 2 patients with the diagnosis of 
chronic viral hepatitis B and in one patient with mixed chronic 
viral hepatitis B+C.  This fact demonstrated a benefic action of 
the three therapy with Interferon gamma+Guna liver+Cytomix. 
These medicines, probably, possess antiviral actions.
Anti-HVC IgM was revealed with the same frequency at 
the start and the end of treatment. This fact demonstrates the 
antiviral properties absence of the hepatitis C virus.
Table 3
The dynamics of biochemistry indices in patients with three therapies  
at the treatment’s start and finish and of the control group
Biochemistry  indices
At the treatment’s start At the treatment’s finish
HVBC
n = 8
HVCC
n = 7
HVBB+
HVCC
n = 2
HVBC
n = 7
HVCC
n = 5
HVBB+
HVCC
n = 2
ALAT (increased) 7 6 2 5 2 1
ASAT (increased) 5 4 1 5 4 1
Bilirubin (increased) 1 (Syndrome Gilbert)
2 (Syndrome 
Gilbert) -
2 (Syndrome 
Gilbert)
1 (Syndrome 
Gilbert) -
Thymol test (increased) 4 5 1 4 5 1
Prothrombinic Index
(decreased till 70%) 1 2 1 1 1 1
Table 4
The dynamics of biochemistry indices in patients of the control group
Biochemistry indices
At the observation’ s start At the observation’s finish
HVBC
n = 6
HVCC
n = 8
HVBB+
HVCC
n = 2
HVBC
n = 6
HVCC
n = 8
HVBB+
HVCC
n = 2
ALAT (increased) 4 5 1 4 4 1
ASAT (increased) 4 4 - 4 5 1
Bilirubina (increased) 3 1 - 3 - -
Thymol test (increased ) 3 1 2 1 2 -
Prothrombinic Index (decreased) 2 3 2 2 2 -
Table 5
The dynamics of markers (serologic indices) in patients of the experimental group and of the control group
Markers
at the start of treatment at the end of treatment
HVBC
n = 8
HVCC
n = 7
HVBC+
HVCC
n = 2
HVBC
n = 8
HVCC
n = 7
HVBC+
HVCC
n = 2
AgHBe 1 - - 1 - -
Anti-HBe 7 - 2 7 - 2
Anti-HBs - - - 2 - 1
Anti-HVC IgM - 7 2 - 7 2
Table 6
The dynamics of viral markers in patients of the control group
Markers
at the start of observations at the end of observations
HVBC
n = 6
HVCC
n = 8
HVBB+
HVCC
n = 2
HVBC
n = 6
HVCC
n = 8
HVBB+
HVCC
n = 2
AgHBe - - - - - -
Anti-HBe 6 - 1 6 - 1
Anti-HBs 0 - - 0 - 0
Anti-HVC IgM - 6 1 - 6 1
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In of the control group (tab. 6) demonstrates the absence 
of AgHBe in patients being in the study with chronic viral he-
patitis B, but there were revealed antibodies anti-HBe.  There 
were not revealed cithers AgHBe or anti-HBe in one patient 
with the diagnosis of mixed chronic viral hepatitis B+C.  This 
fact represents one mutation on the level of AgHBe in chronic 
viral hepatitis with the virus B.  Anti-HBs had not formed in 
10 patients with hepatic virus B.  Anti-HBs had formed in 
3 patients from 10 in control group (30%) and in 1 patient 
treated with Cytomix.
Data from the tab. 7 show a T cell immunosuppression at 
the treatment’s start in patients with the diagnosis HVBC: in 
III degree – 37.5%, II degree – 50% with a concomitant lym-
phocytosis B increase in 75% patients.  There was determined 
Table 7
The dynamics of immunological indices in patients treated  
with Cytomix+Guna liver+Interferon gamma at the treatment’s start and at the end of it
Indices Normal values
At the treatment’s start At  the treatment’s end
HVBC
n = 8
HVCC
n = 7
HVBC+
HVCC
n = 2
HVBC
n = 8
HVCC
n = 7
HVBC+
HVCC
n = 2
Leucocytes (109/l) 4.5-8.0  7.625 ± 0.851 5.828 ± 0.459 5.05 ± 0.45 7.162 ± 1.08   6.614 ± 0.914 5.0 ± 0.6
Lymphocytes (%) 22-38 31.625 ± 2.499  32.142 ± 3.261       40 ± 4 35.125 ± 3.286 33.428 ± 3.379      35.5 ± 0.5
Lymphocytes (109/l) 1.2-2.4  2.395 ± 0.309  1.775 ± 0.182 2.06 ± 0.36   2.393 ± 0.277   2.085 ± 0.219  1.8 ± 0.3
Lymphocytes Ta (%) 20-34    21.5 ± 2.352       19 ± 3.199    19.5 ± 8.5 19.375 ± 2.583     18.428 ± 1.95 20.5 ± 3.5
Lymphocytes Ta (109/l) 0.3-0.7  0.517 ± 0.103  0.364 ± 0.072 0.45 ± 0.25   0.505 ± 0.108     0.402 ± 0.062   0.4 ± 0.1
Lymphocytes Ttot (%) 55-75 45.625 ± 3.035 40.857 ± 2.364    40.5 ± 1.5        45 ± 4.246   45.285 ± 4.892   53.5 ± 19.5
Lymphocytes Ttot (109/l) 0.9-1.5 1.072 ± 0.197   0.755 ± 0.112 0.86 ± 0.16   1.178 ± 0.222     0.985 ± 0.166   0.91 ± 0.19
Lymphocytes Tterm (%) 0-5   4.75 ± 2.335   4.571 ± 1.862 6 ± 4 0 0 0
Lymphocytes Tterm (109/l) 0-0.09 0.126 ± 0.072 0,085 0.135 ± 0.105 0 0 0
Lymphocytes TFR-E-RFC (%) 38-58 28.875 ± 2.286 26.428 ± 2.457       25 ± 2 28.625 ± 2.764   31.428 ± 3.329  37.5 ± 11.5
Lymphocytes TFR-E-RFC (109/l) 0.7-1.1    0.71 ± 0.128  0.491 ± 0.096 0.52 ± 0.13    0.756 ± 0.114     0.677 ± 0.122  0.67 ± 0.07
Lymphocytes TFS (%) 12-28 16.75 ± 1.997 14.428 ± 1.659    15.5 ± 0.5  16.875 ± 2.191    13.428 ± 2.021 16 ± 8
Lymphocytes TFS (109/l) 0.23-0.43 0.406 ± 0.077   0.252 ± 0.032 0.315 ± 0.045    0.448 ± 0.103      0.275 ± 0.041   0.265 ± 0.095
Lymphocytes EAC-RFC (%) 9-18      31 ± 3.835 26.428 ± 2.715    25.5 ± 1.5   33.75 ± 4.934    25.285 ± 3.727 35.5 ± 4.5
Lymphocytes EAC-RFC (109/l) 0.18-0.32 0.753 ± 0.156 0.481 ± 0.085 0.525 ± 0.125    0,873 ± 0,178     0.482 ± 0.053   0.655 ± 0.185
CIC (U.E.) ≤ 60 42.625 ± 8.635       72 ± 29.125       67 ± 22         41 ± 9.924   51.166 ± 34.82 133.5 ± 26.5
LTL 4-7    7.78 ± 0.718 8.422 ± 1.080 5.95 ± 0.55    6.756 ± 0.753      7.171 ± 0.722   5.85 ± 1.85
T/B 2.0-5.0 1.632 ± 0.204 1.628 ± 0.124 1.6    1.512 ± 0.182      2.028 ± 0.395   1.625 ± 0.775
TFR/TFS 2.0-4.0 1.992 ± 0.370     2.0 ± 0.303 1.6 ± 0.2    1.862 ± 0.265      2.442 ± 0.218   2.675 ± 0.575
Table 8
The dynamics of immunological indices in control group of patients at the start and end of treatment
Indices
Normal 
values
At the observation’s start At the observation’s end
HVBC
n = 6
HVCC
n = 8
HVBC+
HVCC
n = 2
HVBC
n = 6
HVCC
n = 8
HVBC+
HVCC
n = 2
Leucocytes (109/l) 4.5-8.0       5.6 ± 0.700  5.775 ± 0.480 5.55 ± 1.15    5.5 ± 0.705 4.937 ± 0.546  5.15 ± 0.85
Lymphocytes (%) 22-38 34.333 ± 2.333  35.625 ± 2.87       40 ± 7  39.333 ± 4.247  36.125 ± 2.247  34.5 ± 4.5
Lymphocytes (109/l) 1.2-2.4   1.961 ± 0.230   2.081 ± 0.254 2.13 ± 0.07 2.205 ± 0.405 1.812 ± 0.245  1.75 ± 0.05
Lymphocytes Ta (%) 20-34 15.333 ± 2.788   17.25 ± 1.655    15.5 ± 3.5  13.166 ± 2.056 14.75 ± 1.760  18.5 ± 8.5
Lymphocytes Ta (109/l) 0.3-0.7   0.288 ± 0.036   0.366 ± 0.060 0.345 ± 0.045 0.338 ± 0.089 0.272 ± 0.042  0.35 ± 0.15
Lymphocytes Ttot (%) 55-75 42.666 ± 4.038 37.125 ± 1.949       41 ± 2  34.666 ± 3.938  34.875 ± 3.943  39.5 ± 9.5
Lymphocytes Ttot (109/l) 0.9-1.5    0.873 ± 0.147 0.781 ± 0.101 0.85 ± 0.05 0.823 ± 0.197 0.687 ± 0.125    0.7 ± 0.2
Lymphocytes Tterm (%) 0-5    0.666 ± 0.494 0.5 ± 0.5 1 ± 1 0.166 ± 0.372 0 0
Lymphocytes Tterm (109/l) 0-0.09    0.013 ± 0.011 0.015 ± 0.015  0.02 ± 0.02 0.001 ± 0.001 0 0
Lymphocytes TFR-E-RFC (%) 38-58 30.166 ± 2.676  26.125 ± 2.614 26.5 ± 0.5  24.833 ± 2.903 22.25 ± 2.403     30 ± 9
Lymphocytes TFR-E-RFC (109/l) 0.7-1.1   0.595 ± 0.092 0.551 ± 0.088   0.575 ± 0.025 0.586 ± 0.132 0.433 ± 0.085  0.55 ± 0.15
Lymphocytes TFS (%) 12-28      12.5 ± 1.979 11.25 ± 1.221 14.5 ± 2.5 9.833 ± 1.777  12.625 ± 2.419    9.5 ± 0.5
Lymphocytes TFS (109/l) 0.23-0.43    0.255 ± 0.052 0.226 ± 0.041   0.305 ± 0.065 0.231 ± 0.062 0.238 ± 0.059 0.165 ± 0.015
Lymphocytes EAC-RFC (%) 9-18  21.666 ± 2.333 22.25 ± 2.160 24.5 ± 4.5  16.166 ± 3.070  18.375 ± 4.597   24.5 ± 0.5
Lymphocytes EAC-RFC (109/l) 0.18-0.32      0.43 ± 0.074 0.456 ± 0.060   0.525 ± 0.115 0.356 ± 0.076 0.361 ± 0.107 0.43 ± 0.02
CIC (U.E.) ≤ 60   46.333 ± 2.564  54.125 ± 12.99    80 ± 15 55.666 ± 14.061  90.375 ± 27.56 38.5 ± 31.5
LTL 4-7      7.066 ± 0.828    8.168 ± 0.99 6,5 ± 1     7.8 ± 0.977 8.125 ± 0.909 7.65 ± 0.95
T/B 2.0-5.0      2.191 ± 0.442  1.768 ± 0.171   1.725 ± 0.225 2.483 ± 0.406 2.731 ± 0.539 1.605 ± 0.355
TFR/TFS 2.0-4.0      2.988 ± 1.336  2.668 ± 0.538   1.875 ± 0.375 3.058 ± 0.858 2.017 ± 0.302 3.1 ± 0.8
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a T cell immunosuppression amelioration till normal values at 
the end  of treatment - in 37.5% patients, but with the B lymp-
hocytosis maintenance of various degrees- in 87.5% patients.
There was determined an immunosupression: III degree 
- in 14.3%, II degree - in 71.4% and a B lymphocytosis II de-
gree – in 57.1%, an increased level of CIC – in 28.5% patients 
with HVCC. 
An amelioration of the immunosuppression till normal 
values was determined in 42.8%, with the normalization of 
B lymphocytosis – in 57.1% patients at the end of treatment, 
but in 42.8% it had revealed a tendency to a B lymphocytosis 
increase in I degree as a result of the humoral reactivity.  CIC 
returned to normal limits in 85.7% and only in one single 
patient it persisted at increased values, but  there were consi-
derably decreased – approximately twice (14.3%).
There were not found positive modifications in patients 
with the diagnosis mixed chronic hepatitis B+C after treat-
ment.  Probably this fact was conditioned by patients a small 
number.
Tab. 8 shows a T cell immunosuppression persistence in 
all patients from control group in II and III degree, that con-
stitutes 81.3% and a B lymphocytosis in II degree in 68.7%, 
CIC with a high level – in 18.75% at the treatment start and 
with a tendency for increase in 43.7% during the study. These 
data confirm the need in an immunomodulator treatment.
Conclusions
The combined treatment with Cytomix+Guna 
liver+Interferon gamma had contributed to:
 - the amelioration of clinical symptomathology in patients 
with HVBC, HVCC and HVBC+HVCC;
 - the liver and spleen dimensions had normalized in all 
patients from the study, but more frequently in patients with 
HVBC (above 50% of cases) comparatively with patients from 
control group.
There were found hepatomegaly and spleenomegaly in 
patients of control group with the same frequency before and 
after treatment:
-  there was a moderate decrease of the cytolysis index 
value (ALAT, ASAT);
- there was established a seroconversion in the AgHBs 
system in 2 from 8 patients with the diagnosis of HVBC and 
in 1 from 2 with the diagnosis of HVBC+HVCC;
- the formation of anti-HBs (protective antibodies) com-
paratively with AgHBs in 3 patients suggests us that these 
medicines possess probably antiviral capacities.
Anti HVC IgM had been revealed with the same frequency 
in patients with HVCC both at the start and the end of treat-
ment, that means a possible antiviral capacity in C hepatic 
virus had not confirmed:
- it was found an amelioration of immune status, which 
was more marked in patients with HVCC.
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Клиническая эффективность цитиколина в комплексном лечении 
постреанимационного синдрома
К. Зубарев, И. Байдауз, С. Зота, К. Максим, В. Стерпу, К. Гуцу-Бахов, Б. Скурту
Отделение реанимации и интенсивной терапии  
Муниципальная Клиническая Больница «Святая Троица», Кишинёв
K. Zubarev, I. Baidauz, C. Zota, K. Maxim, V. Sterpu, K. Gutsu-Bahov, B. Scurtu 
Citicoline Clinical Efficiency in Intensive Therapy of Postresuscitation Syndrome
The problem of global cerebral dysfunction occupies the important place in the postresuscitation syndrome (PRS) clinic.  The problems of 
effective treatment of this dysfunction are still valid today.  Recently, for the CNS dysfunctions correction Piracetam has been used.  The results 
of clinical research of two patient’s groups (group A and B) with PRS after a successful resuscitation that during standard therapy were included 
in treatment Citicoline and Piracetam, respectively, have been presented.  The citicoline positive influence in PRS clinic on the level of broken 
consciousness, duration of its violation and on the progressive renewal of mental dysfunctions has been shown.  Also, the clinical results of the 
Citicoline use for patients with PRS have been argued.
Key words: postresuscitation syndrome, global cerebral dysfunction, Citicoline, Piracetam.
